Last reviewed · How we verify

NCT07517913: neURO

Cerebrospinal Fluid Kinetics of Urolithin A

Not yet recruiting NA Last updated 13 April 2026
What this trial tests

NA trial testing Mitopure in Healthy Adult in 40 participants. Not yet recruiting.

Timeline
1 May 2026
Primary endpoint
1 April 2027
1 April 2027

Quick facts

Lead sponsorAmazentis SA
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposebasic science
Enrollment40
Start date1 May 2026
Primary completion1 April 2027
Estimated completion1 April 2027
Sites1 location across India

Drugs / interventions tested

Conditions studied

Sponsor

Amazentis SA — full company profile →

Who can join

18 and older, any sex, with Healthy Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the impact of Mitopure® consumption on urolithin A (UA) kinetics in cerebral spinal fluid (CSF).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Mitopure

Trials testing the same drug.

Other recruiting trials for Healthy Adult

Currently open trials in the same condition.

Other Amazentis SA trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07517913.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing